Presentation is loading. Please wait.

Presentation is loading. Please wait.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

Published byΠλούτων Φλέσσας Modified over 5 years ago

Similar presentations

Presentation on theme: "A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according."— Presentation transcript:

1 A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according to radiographic responders (blue) or nonresponders (black). A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according to radiographic responders (blue) or nonresponders (black). B, Percentage change in BRAFV600E cfDNA fraction versus percent change in radiographic volume of target lesions at the time of first restaging (after 4 doses of treatment), according to radiographic responders (black) or nonresponders (red). Representative trends in cfDNA fraction (black) and radiographic changes (red) for patients with radiographic response (C) and progression (D). David S. Hong et al. Cancer Discov 2016;6: ©2016 by American Association for Cancer Research

Download ppt "A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according."

Similar presentations

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:1851-1857.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
Dose-escalation patient response.

Dose-escalation patient response.
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation by Bethan Psaila, James B. Bussel, Matthew.

In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation by Bethan Psaila, James B. Bussel, Matthew.
A, baseline and 4-week PET scan from patient 2 (MET c

A, baseline and 4-week PET scan from patient 2 (MET c
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)
Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.
AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
Issue Highlights Clinical Gastroenterology and Hepatology

Issue Highlights Clinical Gastroenterology and Hepatology
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases  Elizabeth O. Stenger, Kuang-Yueh Chiang, Ann.

Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases  Elizabeth O. Stenger, Kuang-Yueh Chiang, Ann.
AG-221 can reduce intracellular 2HG levels and induce differentiation in primary human IDH2R140Q- or IDH2R172K-mutant AML patient samples treated ex vivo.

AG-221 can reduce intracellular 2HG levels and induce differentiation in primary human IDH2R140Q- or IDH2R172K-mutant AML patient samples treated ex vivo.
Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.
Expression of apocrine markers at various stages of apocrine carcinoma progression. Expression of apocrine markers at various stages of apocrine carcinoma.

Expression of apocrine markers at various stages of apocrine carcinoma progression. Expression of apocrine markers at various stages of apocrine carcinoma.
Hospital-level procedural sedation rates among pediatric patients in the earliest year, (2009, red circle) and the most recent year (2014, blue bar). Hospital-level.

Hospital-level procedural sedation rates among pediatric patients in the earliest year, (2009, red circle) and the most recent year (2014, blue bar). Hospital-level.
Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)
Number of 0.5-Mb windows with chromosome lesions that reached statistical significance across patients in early (BE early and BE instability) and late.

Number of 0.5-Mb windows with chromosome lesions that reached statistical significance across patients in early (BE early and BE instability) and late.
Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)
BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

Similar presentations

Ads by Google